Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Featured sites

Sites that work closely with us on this trial

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of Ulcerative Colitis, a condition that causes inflammation and sores in the digestive tract. The study will explore the effectiveness of two treatments: Eltrekibart and Mirikizumab. Eltrekibart is a type of medication known as a monoclonal antibody, which is designed to target specific proteins in the body that may contribute to inflammation. Mirikizumab, also known by its code name LY3074828, is another monoclonal antibody that works by targeting different proteins involved in the inflammatory process.

The purpose of this study is to determine if Eltrekibart alone is more effective than a placebo in helping patients achieve remission, which means a reduction or disappearance of symptoms. The study will involve adult patients who have moderately to severely active Ulcerative Colitis. Participants will receive either Eltrekibart alone, Mirikizumab alone, a combination of both, or a placebo. The study will last for several weeks, with the main goal being to see how many participants achieve remission by the end of the study period.

Throughout the study, participants will receive their treatments through injections or infusions, depending on the medication. The study will monitor the participants' health and response to the treatment over time. The results will help determine the potential benefits of using these medications for treating Ulcerative Colitis and may provide new insights into managing this condition more effectively.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm the diagnosis of ulcerative colitis and evaluate the severity of the condition. This involves reviewing medical history and current symptoms.

  2. Step 2

    Medication administration

    Participants receive the study medication, which may include eltrekibart alone or in combination with mirikizumab. The medication is administered as a solution for injection or solution for infusion.

    The dosage and frequency of administration are determined based on the study protocol and the participant's specific needs.

  3. Step 3

    Monitoring and follow-up

    Regular monitoring is conducted to assess the participant's response to the treatment. This includes evaluating symptoms and any side effects experienced.

    Follow-up visits are scheduled to ensure the participant's safety and to adjust treatment as necessary.

  4. Step 4

    Evaluation of clinical remission

    At week 12, the primary endpoint is evaluated. This involves determining the proportion of participants who achieve clinical remission, which means a significant reduction or absence of symptoms.

  5. Step 5

    Completion of study participation

    Upon completion of the study period, participants undergo a final assessment to evaluate the overall effectiveness of the treatment and any long-term effects.

    Participants are provided with information regarding their health status and any necessary follow-up care.

Who can join the trial?

8 criteria

  • Have had a confirmed diagnosis of Ulcerative Colitis (UC) for at least 3 months before starting the study. UC is a condition that causes inflammation and sores in the colon.
  • Have UC that is considered moderately to severely active, as determined by a specific scoring system used by doctors.
  • Have not responded well to, stopped responding to, or cannot tolerate at least one standard medication (like corticosteroids) or one advanced treatment (such as biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators). These are types of medicines used to treat UC.
  • Are taking a stable dose of certain oral medications for UC, including corticosteroids. This means the dose of the medication has not changed recently.
  • Must follow specific rules regarding contraception. This means using methods to prevent pregnancy during the study.
  • Both males and females can participate in the study.
  • The study includes people from certain age groups, which are typically adults.
  • The study may include individuals considered part of a vulnerable population, which means they might need extra protection or care.

Who cannot join the trial?

8 criteria

  • Participants with other serious health conditions that could interfere with the study.
  • Individuals who have had recent surgery related to their digestive system.
  • People who are currently using certain medications that might affect the study results.
  • Participants who have a history of severe allergic reactions.
  • Individuals who are pregnant or breastfeeding.
  • People who have participated in another clinical trial recently.
  • Participants with a history of substance abuse.
  • Individuals who are unable to follow the study procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Eltrekibart

    is a medication being studied to see if it can help people with moderately to severely active ulcerative colitis achieve clinical remission. It is being tested to determine its effectiveness when used alone.

  • Mirikizumab

    is another medication involved in the study. It is being tested in combination with eltrekibart to see if the combination is more effective in treating ulcerative colitis than eltrekibart alone.

What is already known about the treatment

  • Eltrekibart

    Eltrekibart is administered orally and is currently being studied in clinical trials for its effectiveness in treating moderately to severely active ulcerative colitis. It is not yet widely recognized in medical literature as it is still under investigation. The main therapeutic indication for eltrekibart is to induce clinical remission in patients with ulcerative colitis. At the molecular level, it works by modulating specific pathways involved in inflammation, although the exact mechanism is still being researched. It is classified pharmacologically as an anti-inflammatory agent.

  • Mirikizumab

    Mirikizumab is administered via injection and is being evaluated in combination with eltrekibart for the treatment of ulcerative colitis. It is currently in clinical trials and not yet fully established in medical practice. The primary therapeutic use of mirikizumab is to help reduce inflammation in patients with ulcerative colitis. It acts by targeting specific proteins involved in the inflammatory process, helping to decrease immune system activity. Mirikizumab is classified as a monoclonal antibody.

Investigated diseases

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum. It causes inflammation and ulcers in the innermost lining of the large intestine. Symptoms often include abdominal pain, diarrhea, and rectal bleeding. The disease typically progresses with periods of flare-ups and remissions. Over time, the inflammation can lead to complications such as narrowing of the colon or increased risk of colon cancer. The exact cause is unknown, but it is believed to involve an abnormal immune response.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507853-13-00Protocol codeI7P-MC-DSAGEstimated enrolment648 patientsSponsorEli Lilly & Co.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).